A Phase 1 interventional study of Telmisartan/Amlodipin FDC and Telmisartan in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Japan. Open to male participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-03-28.
Sponsored by Boehringer Ingelheim · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To investigate the bioequivalence of telmisartan administrated in two different ways: both in telmisartan 80 mg/amlodipine 5 mg fixed-dose combination tablets (T) and as telmisartan 80 mg tablet and amlodipine 5 mg tablets (R) in concomitant use
Purpose:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single-dose, four-period replicated crossover design
Drug: Telmisartan/Amlodipin FDC
single-dose, four-period replicated crossover design
Drug: Telmisartan · Drug: Amlodipin
Telmisartan80mg/Amlodipin5mg FDC
Telmisartan 80 mg tablet
Amlodipin 5mg tablet
AUC0-tz
Area under the concentration-time curve of Telmisartan in plasma over the time interval from 0 to the time of the last quantifiable data point
Time frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration
Cmax
maximum measured concentration of Telmisartan in plasma
Time frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration
AUC0-∞
area under the concentration-time curve of Telmisartan in plasma over the time interval from 0 extrapolated to infinity
Time frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration
Tmax
time from dosing to the maximum concentration of Telmisartan in plasma
Time frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration
λz
terminal rate constant of Telmisartan in plasma
Time frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration
t1/2
terminal half-life of Telmisartan in plasma
Time frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration
MRTpo
mean residence time of Telmisartan in the body after oral administration
Time frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration
| Milestone | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Started | 32 | 32 |
| Completed | 32 | 32 |
| Not completed | 0 | 0 |
| Milestone | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Started | 32 | 32 |
| Completed | 32 | 31 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Started | 32 | 31 |
| Completed | 32 | 31 |
| Not completed | 0 | 0 |
| Milestone | Treatment Sequence A | Treatment Sequence B |
|---|---|---|
| Started | 32 | 31 |
| Completed | 32 | 31 |
| Not completed | 0 | 0 |
Area under the concentration-time curve of Telmisartan in plasma over the time interval from 0 to the time of the last quantifiable data point
| ng*hour/mL | T80/A5 mg FDC Tablet | T80mg Tablet and A5 mg Tablet in Concomitant Use |
|---|---|---|
| AUC0-tz | 1970 ± 67.9 | 1950 ± 67.0 |
maximum measured concentration of Telmisartan in plasma
| ng/mL | T80/A5 mg FDC Tablet | T80mg Tablet and A5 mg Tablet in Concomitant Use |
|---|---|---|
| Cmax | 471 ± 88.1 | 484 ± 81.8 |
area under the concentration-time curve of Telmisartan in plasma over the time interval from 0 extrapolated to infinity
| ng*hour/mL | T80/A5 mg FDC Tablet | T80mg Tablet and A5 mg Tablet in Concomitant Use |
|---|---|---|
| AUC0-∞ | 2410 ± 60.4 | 2300 ± 62.4 |
time from dosing to the maximum concentration of Telmisartan in plasma
| hour | T80/A5 mg FDC Tablet | T80mg Tablet and A5 mg Tablet in Concomitant Use |
|---|---|---|
| Tmax | 0.750 ± 0.500 | 0.750 ± 0.250 |
terminal rate constant of Telmisartan in plasma
| /hour | T80/A5 mg FDC Tablet | T80mg Tablet and A5 mg Tablet in Concomitant Use |
|---|---|---|
| λz | 0.0297 ± 52.5 | 0.0326 ± 45.1 |
terminal half-life of Telmisartan in plasma
| hour | T80/A5 mg FDC Tablet | T80mg Tablet and A5 mg Tablet in Concomitant Use |
|---|---|---|
| t1/2 | 23.3 ± 52.5 | 21.3 ± 45.1 |
mean residence time of Telmisartan in the body after oral administration
| hour | T80/A5 mg FDC Tablet | T80mg Tablet and A5 mg Tablet in Concomitant Use |
|---|---|---|
| MRTpo | 21.8 ± 56.2 | 19.9 ± 50.5 |
Collected over From signing the informed consent onwards through the observational phase. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Sequence A | — | 0/32 (0%) | 0/32 (0%) |
| Treatment Sequence B | — | 0/32 (0%) | 0/32 (0%) |
| Age, Continuous(Year) | Treatment Sequence A | Treatment Sequence B | Total |
|---|---|---|---|
| Mean | 24.1 ± 3.3 | 24.5 ± 3.8 | 24.3 ± 3.5 |
| Sex: Female, Male(Participants) | Treatment Sequence A | Treatment Sequence B | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 32 | 32 | 64 |
The record gives a start of Apr 2011 and a primary completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Telmisartan